The therapeutic effect of metadoxine on alcoholic and non-alcoholic steatohepatitis;A metadoxin terápiás hatásának összehasonlítása alkoholos és nem alkoholos zsírmájban

Orvosi Hetilap

Volumn 146, Issue 47, 2005, Pages 2409-2414

  Váli, László ^a,b   Blázovics, Anna ^a   Fehér, János ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b NONE   (Hungary)

Author keywords

Metadoxine; Non alcoholic fatty liver; Redox homeostasis

Indexed keywords

FREE RADICAL; GLUTATHIONE; METADOXINE; DRUGS USED IN THE TREATMENT OF ADDICTION; PYRIDOXINE; PYROGLUTAMIC ACID;

ALCOHOL LIVER DISEASE; ALCOHOLISM; ARTICLE; DRUG EFFECT; DRUG EFFICACY; FATTY LIVER; HUMAN; LIVER INJURY; PATHOPHYSIOLOGY; QUALITY OF LIFE; ALCOHOL INTOXICATION; ALCOHOLIC FATTY LIVER; DRUG COMBINATION; HEPATITIS; METABOLISM; REVIEW;

ALCOHOL DETERRENTS; ALCOHOLIC INTOXICATION; ALCOHOLISM; DRUG COMBINATIONS; FATTY LIVER; FATTY LIVER, ALCOHOLIC; GLUTATHIONE; HEPATITIS; HEPATITIS, ALCOHOLIC; HUMANS; PYRIDOXINE; PYRROLIDONECARBOXYLIC ACID; QUALITY OF LIFE;

EID: 33644870857     PISSN: 00306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Addolorato, G., Ancona, C., Capristo, E. és mtsa: Metadoxine in the treatment of acute and chronic alcoholism: a review. Int. J. Immunopath. Ph., 2003, 16, 207-214.
2. Annoni, G., Contu, L., Tronci, M. A. és mtsai: Pyridoxol L,2-pyrrolidon-5 carboxylate prevents active fibroplasia in CCl4-treated rats. Pharmacol. Res., 1992, 25, 87-93.
3. Arosio, B., Santambrogio, D., Gagliano N. és mtsa: Changes in expression of the albumin, fibronectin and type I procollagen genes in CCl4-induced liver fibrosis: effect of pyridoxol L,2-pyrrolidon-5 carboxylate. Pharmacol Toxicol., 1993, 73, 301-304.
4. Baldacci, M., Catalani, R., Bartoli, C. és mtsa: Effects of pyridoxine-pyrrolidone-carboxylate on hepatic adenosine triphosphate levels in rats. Bollettino - Societa Italiana Biologia Sperimentale., 1982, 58, 1643-1649.
5. Bono, G., Sinforiani, E., Merlo, P. és mtsai: Alcoholic abstinence syndrome: short-term treatment with metadoxine. Int. Jl. Clin. Pharm. Res., 1991, 11, 35-40.
6. Caballeria, J., Pares, A., Bru, C. és mtsai: Metadoxine accelerates fatty liver recovery in alcoholic patients: results of a randomized double-blind, placebo-control trial. Spanish Group for the Study of Alcoholic Fatty Liver. J Hepatol., 1998, 28, 54-60.
7. Calabrese, V., Randazzo, G., Ragusa, N. és mtsa: Long-term ethanol administration enhances age-dependent modulation of redox state in central and peripheral organs of rat: protection by metadoxine. Drug. Exp. Clin. Res., 1998, 24, 85-91.
8. Calabrese, V., Calderone, A., Ragusa, N. és mtsa: Effects of Metadoxine on cellular status of glutathione and of enzymatic defence system following acute cthanol intoxication in rats. Drug. Exp. Clin. Res., 1996, 22, 17-24.
9. Calabrese, V., Calderone, A., Ragusa, N. és mtsa: Effects of metadoxine on cellular formation of fatty acid ethyl esters in ethanol treated rats. Int. J. Tissue. React., 1995, 17, 101-108.
10. Calabrese, V., Bombaci, G., Calderone, A. és mtsa: Effects of metadoxine on cellular free fatty acid levels in ethanol treated rats. Int. J. Tissue. React., 1993, 15, 235-243.
11. Corsini, G., Gelso, E., Giuliano G.: Effects of metadoxine on main biohumoral changes induced by chronic alcoholism. Clinica. Terapeutica., 1992, 140, 251-257.
12. Cortez-Pinto, H., Chatham, J., Chacko, V. P. és mtsai: Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA, 1999, 282, 1659-1664.
13. Diaz Martinez, M. C., Diaz Martinez, A., Villamil Salcedo, V. és mtsa: Efficacy of metadoxine in the management of acute alcohol intoxication. J. Int. Med. Res., 2002, 30, 44-51.
14. Fehér, J., Lengyel, G.: A new approach to drug therapy in non-alcoholic steatohepatitis (NASH). J. Int. Med. Res., 2003, 31, 537-551.
15. Fornai, F., Grazia Alessandri, M., Bonuccelli, U. és mtsai: Effect of metadoxine on striatal dopamine levels in C57 black mice. J. Pharm. Pharmacol., 1993, 45, 476-478.
16. Felicioli, R., Saracchi, I., Flagiello, A. M. és mtsa: Effects of pyridoxine-pyrrolidon-carboxylate on hepatic and cerebral ATP levels in ethanol treated rats. Int. J. Clin. Pharm. Ther., 1980, 18, 277-280.
17. Garau, B., Fadda, F., Melis, F. és mtsai: Metadoxine (pyrrolidone carboxylate of pyridoxine) antagonizes the locomotor-stimulatory effect of ethanol in mice. Alcohol Alcoholism, 1992, 27, 501-504.
18. Gessa, G. L.: Guidelines for the drug therapy of alcoholism. Recenti Progressi in Medicina., 1990, 81, 171-175.
19. Gutierrez-Ruiz, M. C., Bucio, L., Correa, A. és mtsai: Metadoxine prevents damage produced by ethanol and acetaldehyde in hepatocyte and hepatic stellate cells in culture. Pharm. Res., 2001, 44, 431-436.
20. Hagymási K.: A máj redox homeostasisának tanulmányozása kísérletes és humán vizsgálatokban- antioxidáns betegség. PhD értekezés, Budapest, 2002.
21. Hagymási, K., Blázovics, A., Kocsis, I. és mtsa: Effects of metadoxinea - liver protecting agent on short-term extrahepatic cholestasis. Current topics in biophysics., 2000, 24, 69-73.
22. Hagymási K., Blázovics A.: Antioxidánsok a májvédelemben. Orv. Hetil., 2004, 145, 1421-1425.
23. James, O. F., Day, C. P.: Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J. Hepatol., 1998, 29, 495-501.
24. Marchi, S., Polloni, A., Costa, F. és mtsai: Liver triglyceride accumulation after chronic ethanol administration: a possible protective role of metadoxina and ubiquinone. Int. J. Tissue. React., 1990, 12, 247-250.
25. Metadoxine: Drugs of Today, 1998, 24, 217-219.
26. Muriel, P., Deheza, R.: Fibrosis and glycogen stores depletion induced by prolonged biliary obstruction in the rat are ameliorated by metadoxine. Liver Int., 2003, 23, 262-268.
27. Pár A.: A kezelés lehetoségei alkoholos májbetegségekben. (Absztinencia, táplálkozás, gyógyszerek, májtranszplantáció). Orv. Hetil., 2000, 141, 827-833.
28. Pares, X., Moreno, A., Peralba, J. M. és mtsai: Action of metadoxine on isolated human and rat alcohol and aldehyde dehydrogenases. Effect on enzymes in chronic ethanol-fed rats. Method Find. Exp. Clin., 1991, 13, 37-42.
29. Rizzo, A., Breda, A., Moretto, F. és mtsai: Therapeutic use of metadoxine in chronic alcoholism. Double blind study of patients in a department of general medicine. Clinica Terapeutica., 1993, 142, 243-250.
30. Santoni, S., Corradini, P., Zocchi, M. és mtsai: Metadoxine in alcohol-related pathology. Clinica Terapeutica., 1989, 130, 115-122.
31. Shpilenya, L. S., Muzychenko, A. P., Gasbarrini, G. és mtsai: Metadoxine in acute alcohol intoxication: a double-blind, randomized, placebo-controlled study. Alcohol Clin. Exp. Res., 2002, 26, 340-346.
32. Stefanini, G. F., Addolorato, G., Caputo, F. és mtsai: Treatment of alcoholic fatty liver: is the metabolic effect of metadoxine the only reason for improved liver function? J. Hepatol., 1999, 30, 739-740.
33. Stickel, F., Hoehn, B., Schuppan, D. és mtsa: Review article: Nutritional therapy in alcoholic liver disease. Aliment Pharm Therap., 2003, 18, 357-373.
34. Vedrova, N. N., Gnezdilova, N. I.: Metadoxyl in combined treatment of alcohol damage to the liver. Klinicheskaia Meditsina., 2001, 79, 56-58.